Clinical trial · Interventional
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
Phase II Clinical Study of AK112, an Anti-PD-1 and VEGF Bispecific Antibody, Alone or in Combination With Chemotherapy for the Neoadjuvant/Adjuvant Treatment of Resectable Non-small Cell Lung Cancer
NCT05247684CI-TRIAL-00119735active not recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
AK112, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable NSCLC
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Resectable Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AK112 | Drug | — | UNRESOLVED |
| Carboplatin | Drug | Carboplatin | ALIAS |
| Cisplatin | Drug | Cisplatin | ALIAS |
| Paclitaxel | Drug | Paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- arm 1(AK112)
- description
- Neoadjuvant therapy was 3-4 cycles of AK112(Q3W), followed by surgery ,followed by adjuvant therapy for 16 cycles of AK112(Q3W)
- interventionNames
- Drug: AK112
- type
- EXPERIMENTAL
- label
- arm 2(AK112+Carboplatin/cisplatin + paclitaxel)
- description
- Neoadjuvant therapy was 3-4 cycles of AK112 plus Carboplatin/cisplatin + paclitaxel(Q3W), followed by surgery ,followed by adjuvant therapy for 16 cycles of AK112(Q3W)
- interventionNames
- Drug: AK112
- Drug: Carboplatin
- Drug: Cisplatin
- Drug: Paclitaxel
Primary outcomes (4)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. 18 to 75 years old 2. Be able and willing to provide written informed consent and to comply with all requirements of study participation 3. Histologically confirmed resectable stage II-IIIB NSCLC 4. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 5. Has adequate organ function 6. All female and male subjects of reproductive potential must agree to use an effective method of contraception, as determined by the Investigator, during and for 120 days after the last dose of study treatment. Exclusion Criteria: 1. Is currently participating in a study of an investigational agent or using an investigational device 2. Has an active autoimmune disease that has required systemic treatment in the past 2 years 3. Has an active infection requiring systemic therapy 4. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative\] is detected) 5. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study 6. Has received a live virus vaccine within 30 days prior to first dose of study treatment 7. Is pregnant, breastfeeding, or expecting to conceive or father a child within the projected duration of the study including 120 days following the last dose of study treatment.
References
Publications (0)
Data not yet available
No reference posted for this study.